Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 62, Issue 3, Pages 1181-1198Publisher
IOS PRESS
DOI: 10.3233/JAD-170531
Keywords
Alzheimer's disease; blood proteomic biomarkers; endophenotype; replication; validation
Categories
Funding
- MRC [MR/L023784/1, MR/L023784/2, MC_PC_17215] Funding Source: UKRI
- Medical Research Council [MC_PC_17215, MR/L023784/2, MR/L023784/1] Funding Source: Medline
- NIA NIH HHS [P50 AG005146] Funding Source: Medline
- NATIONAL INSTITUTE ON AGING [P50AG005146, ZIAAG000200] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Blood-based biomarkers represent a less invasive and potentially cheaper approach for aiding Alzheimer's disease (AD) detection compared with cerebrospinal fluid and some neuroimaging biomarkers. Acknowledging that many in the field have made great progress, here we review some of the work that our group has pursued to identify and validate blood-based proteomic biomarkers through both case control and AD pathology endophenotype-based approaches. Our focus is primarily to identify a minimally invasive and hopefully cost-effective blood-based biomarker to reduce screen failure in clinical trials where participants have prodromal or even pre-clinical disease. We summarize some of the key findings and approaches taken in these biomarker studies, while addressing the main challenges, including that of limited replication in the field, and discuss opportunities for biomarker development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available